Research of Exenatide for Overweight/Obese PCOS Patients With IGR

• Status: Completed
• Trial end date: 2018-07-31
• Target enrollment: 0
• Participant gender: Female

Summary

Compare the therapeutic effects of exenatide, metformin and their combination for 3 months on reproductive and metabolic improvements of overweight/obese PCOS patients with impaired glucose regulation.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: RenJi Hospital
• Treatments: Exenatide; Metformin

Criteria

Inclusion Criteria:

1. have PCOS which is diagnosed according to 2003 Rotterdam criteria;

2. overweight / obesity diagnostic criteria is based on WHO-WPR ;

3. IGR diagnostic criteria is based on 1999 WHO diagnostic criteria;

4. have been treated with dietary and behavioral intervention for 3 months but are ineffective;

5. have no use of other hypoglycemic drugs before 3 months of treatment.

Exclusion Criteria:

• Except for serious complications (cardiovascular events and recent significant liver, kidney or lung disease within 3 months)

• high blood pressure (>160/100mmHg)

• active infection

• secondary diabetes

• pregnancy

• alcohol abuse

• allergic to GLP-1 receptor agonist or metformin